LeonaBio Inc
leonabio.comLeonaBio Inc (NASDAQ: LONA) is a clinical-stage biopharmaceutical company that develops small molecule therapeutics for serious diseases. The company has generated no product revenue since its incorporation in March 2011, funding operations through capital raises rather than product sales. Its pipeline is centered on two drug candidates: lasofoxifene, a small molecule in development for conditions including estrogen receptor-positive breast cancer, and ATH-1105, a small molecule being advanced as a potential treatment for ALS and other neurodegenerative diseases following the September 2024 announcement that the Phase 2/3 LIFT-AD trial of fosgonimeton failed to meet its primary or key secondary endpoints. LeonaBio does not manufacture internally, relying on third-party contract development and manufacturing organizations (CDMOs) for preclinical and clinical supply. The company has no approved products and its path to profitability depends entirely on successful clinical development and regulatory approval of one or more drug candidates.
Products & Services
Two drug candidates as of the 10-K filed 2026-03-31: lasofoxifene (small molecule, clinical stage) and ATH-1105 (small molecule, targeting ALS and neurodegenerative diseases). Fosgonimeton was discontinued after the Phase 2/3 LIFT-AD trial failure announced September 2024.
Revenue Model
No product revenue has been generated since inception. Operations are funded through equity capital raises, including a PIPE financing completed in December 2025 and the acquisition of Sermonix assets via a pre-funded warrant structure.
Customers & Markets
No commercial customers. End markets, if products reach approval, would be oncology and neurology patients, with physician education and sales infrastructure to be built post-approval. Medicare drug pricing policy is a material regulatory exposure given the Inflation Reduction Act provisions affecting single-source drugs.
Financial Snapshot
Loading...
